Cardalis Cardiac Drug Chewable Tablets provides cardiac health support. Containing 2 active ingredients (spironolactone and benazepril hydrochloride), Cardalis is the only FDA-approved combination drug for managing congestive heart failure. It's suitable for mild, moderate and severe cases and comes in an easily-administered chewable form. Vets commonly prescribe Cardalis with a concurrent therapy, such as furosemide, to help best address the specific health problems. Sold in 30 ct. boxes.How it Works

Mechanism of Action: The main pharmacological target of spironolactone and benazepril is the renin-angiotensin-aldosterone system (RAAS) at different levels in the cascade. Spironolactone and its active metabolites (including 7--thiomethyl-spironolactone and canrenone) act as specific antagonists of aldosterone (regardless of the source) by binding competitively to mineralocorticoid receptors located in the kidneys, heart and blood vessels. Benazepril hydrochloride is a prodrug hydrolyzed in vivo into its active metabolite, benazeprilat. Benazeprilat is a highly potent and selective inhibitor of angiotensin-converting enzyme (ACE), thus preventing the conversion of inactive angiotensin I to active angiotensin II. This prevents deleterious effects of vasoconstriction and aldosterone release, including sodium and water retention, and vascular and myocardial remodeling. However, aldosterone release is not fully controlled by ACE inhibitors because angiotensin II is also produced by non-ACE pathways. Therefore, concomitant use of the aldosterone antagonist spironolactone and the ACE inhibitor benazepril hydrochloride inhibits both ACE and non-ACE pathways.

Special Precautions

Keep away from children and animals. Contraindications: Do not administer CARDALIS in conjunction with non-steroidal anti-inflammatory drugs (NSAIDs) in dogs with renal insufficiency. Do not administer CARDALIS to dogs with hypoadrenocorticism (Addisons Disease), hyperkalemia, or hyponatremia. Do not administer CARDALIS to animals with known hypersensitivity to ACE inhibitors or spironolactone.

Overdose Information

Contact your nearest emergency animal hospital.

Side Effects

The following adverse events were seen in fewer than 5% of the study animals, in decreasing order: urine abnormalities, fluid in abdomen, ataxia, weight loss, digestive tract disorder, hypertension, electrolyte disorder, bronchitis, and hyperactivity. Renal insufficiency was reported more frequently in dogs treated with CARDALIS. This finding may be also attributed to the concurrent administration of furosemide. The incidence of death, including euthanasia and sudden death, was similar in dogs treated with CARDALIS or benazepril hydrochloride. In most cases, death was attributable to the progression of heart disease or the clinical signs associated with congestive heart failure. Deaths of unknown cause were presumed to be cardiac in nature.

Storage

Store at controlled room temperature, 20° to 25°C (68° to 77°F), in original container. Excursions permitted between 15°C and 30°C (between 59° and 86°F).